United Therapeutics (UTHR) Tops Q2 EPS by 18c
FREE Breaking News Alerts from StreetInsider.com!
StreetInsider.com Top Tickers, 10/8/2026
- Wall Street ends lower, off record highs, as Treasury yields climb
- Want to be a stock market bear? BCA says watch potential U.S. tax increases
- SpaceX seeks $40bn in financing for Nvidia chip purchase
- Chip stock could soar nearly 200%, analyst says: "If you don’t buy it, they will"
- Musk rules out TSMC role in Terafab operations; Intel gains
Tweet
Share
E-mail
Get Alerts UTHR Hot Sheet
Price: $545.00 +0.62%
Revenue Growth %: -1.2%
Financial Fact:
Total revenues: 408.2M
Today's EPS Names:
AEHR, VFS, CMTL, More
Revenue Growth %: -1.2%
Financial Fact:
Total revenues: 408.2M
Today's EPS Names:
AEHR, VFS, CMTL, More
Join SI Premium – FREE
United Therapeutics (NASDAQ: UTHR) reported Q2 EPS of $7.27, $0.18 better than the analyst estimate of $7.09. Revenue for the quarter came in at $783.3 million versus the consensus estimate of $807.05 million.
For earnings history and earnings-related data on United Therapeutics (UTHR) click here.
Serious News for Serious Traders! Try StreetInsider.com Premium Free!
You May Also Be Interested In
- Applied Digital (APLD) Tops Q1 EPS by 26c, Beats on Revenue
- Rosenblatt Starts Nebius Group (NBIS) at Buy
- Goldman Sachs Upgrades Rocket Pharmaceuticals (RCKT) to Neutral
Create E-mail Alert Related Categories
EarningsRelated Entities
Earnings, Maynard Um, Mark Zuckerberg, ARKSign up for StreetInsider Free!
Receive full access to all new and archived articles, unlimited portfolio tracking, e-mail alerts, custom newswires and RSS feeds - and more!
